US Patent 10,857,159: Halobetasol Foam Composition Scope, Patent Strength, and Generic Entry Risk

US Patent 10,857,159 protects a narrowly defined, storage-stable halobetasol foam composition. The independent claim requires specific concentration ranges for halobetasol, ethanol, emulsifying wax, cetostearyl alcohol, polyoxyl 20 cetostearyl ether, propylene glycol, water, and trace benzoic acid, together with a hydrocarbon propellant. It also requires a pH of 4.0 to 6.3 and less than 2% halobetasol degradation after 24 months at 25°C.[1]

The patent is strongest against products that reproduce the claimed excipient system and stability profile. It is materially narrower than a claim covering all halobetasol foams or all aerosolized topical corticosteroid formulations.

What does US Patent 10,857,159 claim?

Claim 1 is an independent composition claim. It uses the transitional phrase "consisting of," which generally closes the claimed composition to additional components that materially alter the claimed formulation, subject to the treatment of incidental impurities and conventional claim-construction principles.

Component	Claimed range, weight basis
Halobetasol, or pharmaceutically acceptable salt, ester, or solvate	0.02% to 0.10%
Ethyl alcohol	40% to 60%
Emulsifying Wax, NF	0.1% to 5.0%
Cetostearyl alcohol	0.05% to 1.0%
Polyoxyl 20 cetostearyl ether	0.05% to 1.0%
Propylene glycol	1% to 10%
Water	30% to 40%
Benzoic acid	Greater than 0% and less than 0.0005%
Propellant	Required, but no independent range in claim 1
pH	About 4.0 to 6.3
Halobetasol degradation	Less than 2% after 24 months at 25°C

The claim requires every listed component. A competing product outside one material limitation may avoid literal infringement, although the doctrine of equivalents could remain relevant depending on the substituted ingredient, the prosecution history, and the scope surrendered during examination.

What halobetasol forms are covered?

The claim covers halobetasol itself and "pharmaceutically acceptable salts, esters, and solvates." Halobetasol propionate is the commercially relevant ester form for topical dermatology products. The wording therefore reaches compositions containing halobetasol propionate if the other limitations are satisfied.

The claim does not cover every halobetasol dosage form. A cream, ointment, lotion, gel, solution, shampoo, or non-aerosol foam would not infringe solely because it contains halobetasol. The product must also satisfy the claimed excipient, pH, degradation, and propellant limitations.

How do claims 2 through 4 narrow the patent?

Claims 2 through 4 are dependent claims and add limitations to claim 1.

Claim	Added limitation	Commercial significance
2	Composition is in a canister; propellant is propane, n-butane, isobutane, or a combination at 3.25% to 5.75% w/w	Targets pressurized hydrocarbon aerosol packaging
3	Propellant is 3.5% to 4.0% w/w	Narrows the formulation to a tighter propellant window
4	pH is about 5.0 to 5.5	Targets the preferred acidity range

Claim 3 is narrower than claim 2. A product with 3.7% w/w hydrocarbon propellant would fall within claim 3 if it also satisfies all limitations inherited from claims 1 and 2. A product with 3.0% or 4.5% propellant would not literally meet claim 3, although it could still fall within claim 2 if the remaining limitations are met.

What technical problem does the patent address?

The claim is directed to chemical and physical stability in a low-water, ethanol-rich topical foam. The formulation has several potentially competing design requirements:

Ethanol must remain within a high concentration range to support foam formation and drug solubilization.
Water must remain between 30% and 40%.
Surfactant and fatty-alcohol levels must support emulsion structure and foam quality.
Trace benzoic acid must remain below 0.0005%.
The pH must remain acidic but within the claimed range.
Halobetasol degradation must remain below 2% over 24 months at 25°C.

The degradation limitation is important. It is not merely a composition limitation based on ingredients. It requires a result after a specified storage period and temperature. A party asserting infringement would need reliable evidence concerning the composition at manufacture and its stability data, or evidence sufficient to show that the product necessarily meets the limitation.

How strong is the patent estate for this halobetasol foam formulation?

US 10,857,159 has meaningful formulation value but a limited literal scope.

Strengths

The claim combines multiple structural and performance limitations. A generic manufacturer cannot avoid the patent merely by matching the active ingredient and dosage strength. It must also evaluate:

The identity and concentration of each excipient.
The trace level of benzoic acid.
Product pH.
Propellant composition and loading.
Long-term degradation performance.
The effect of any formulation change on foam delivery and regulatory equivalence.

The claim's low benzoic-acid threshold is particularly restrictive. A formulation using no benzoic acid may avoid the literal requirement that the amount be greater than 0%. A formulation using 0.0005% or more would fall outside the express upper boundary, subject to range construction and measurement precision.

Weaknesses

The patent does not claim:

All halobetasol aerosol foams.
All 0.05% halobetasol products.
All formulations using ethanol and hydrocarbon propellant.
A method of treating plaque psoriasis independent of the formulation.
A manufacturing process independent of the composition.
A device or valve architecture independent of the formulation.

The use of "consisting of" creates a design-around opportunity. A competitor could investigate a formulation with a different emulsifier, a different co-solvent, a different preservative system, a non-hydrocarbon propellant, or a different pH. Each change could affect FDA product comparability and performance, but it may also reduce literal infringement risk.

What design-around strategies could reduce infringement risk?

Potential design-around paths include the following:

Design-around path	Potential effect
Replace or materially alter Emulsifying Wax, NF	Removes a required named component
Use a different nonionic surfactant system	Avoids the claimed polyoxyl 20 cetostearyl ether limitation
Eliminate benzoic acid	Falls outside the "greater than 0%" limitation
Use benzoic acid at or above 0.0005%	Falls outside the stated upper range, subject to claim construction
Change ethanol concentration below 40% or above 60%	Exits the independent claim range
Use a non-hydrocarbon propellant	May avoid claims 2 and 3, but claim 1 still requires a propellant
Use a non-aerosol package	Avoids claims 2 and 3, but not necessarily claim 1
Change pH outside 4.0 to 6.3	Avoids the express pH limitation
Use a different active concentration	May avoid the halobetasol concentration range

These approaches are not equivalent from a regulatory perspective. For a generic topical aerosol, a formulation change can affect product performance, Q1/Q2 sameness, foam characteristics, particle or droplet size, delivery, preservative effectiveness, and stability. A non-infringing formulation may require a more extensive FDA development program than a formulation closely matching the reference product.

What is the patent expiration date?

The enforceable term must be determined from the patent's recorded application data, priority chain, patent-term adjustment, patent-term extension, terminal disclaimers, and any post-grant changes. The issue date alone does not establish the expiration date.

For a patent issued from a modern nonprovisional application, the baseline term is generally 20 years from the earliest effective nonprovisional filing date, subject to statutory adjustments.[2] US 10,857,159 issued on December 8, 2020.[1] The relevant commercial question is therefore not the issue date but the patent's calculated expiration date and whether the patent is listed for the applicable FDA product.

A patent term extension under 35 U.S.C. § 156 is generally associated with regulatory review of an approved drug product. Patent-term adjustment under 35 U.S.C. § 154 can extend the term for USPTO examination delays. Those calculations should be separated from Orange Book listing status.

What is the Orange Book status of US 10,857,159?

The Orange Book question cannot be answered from the claim text alone. Orange Book listing is product-specific. It depends on whether the patent owner or NDA holder submitted the patent for listing against a particular approved drug and whether FDA accepted the listing.

For a halobetasol aerosol foam, an Orange Book analysis should distinguish:

Drug substance patents.
Drug product or formulation patents.
Method-of-use patents.
Patents listed against the reference NDA.
Delisted, expired, or withdrawn patents.
Any pediatric exclusivity attached to the listed patent term.

If the patent is listed against the reference product, an ANDA applicant may need to make a Paragraph IV certification asserting that the patent is invalid, unenforceable, or will not be infringed.[3] If the patent is not listed, it may still create ordinary patent infringement risk, but it would not necessarily trigger the same ANDA certification and litigation framework.

What Paragraph IV risks apply to a generic halobetasol foam?

A generic applicant seeking approval before patent expiry could face four principal outcomes:

Paragraph IV certification and no suit. FDA may approve after the statutory waiting period if the NDA holder does not sue.
Paragraph IV litigation. A suit filed within 45 days can trigger a 30-month stay of approval, subject to statutory exceptions and court decisions.
Formulation design-around. The applicant may submit a product outside the listed claims, reducing direct infringement exposure.
Delayed launch or settlement. The parties may resolve the dispute through a settlement that sets an agreed launch date or other terms.

Claim 1 creates a formulation-specific infringement analysis. A generic applicant using the same or substantially equivalent excipients may face testing and discovery disputes over the benzoic-acid amount, pH, propellant content, and 24-month degradation result. Claims 2 and 3 provide narrower but potentially clearer targets if the generic uses a hydrocarbon propellant in the claimed range.

What patent litigation and settlement issues affect the patent?

A complete litigation assessment requires the federal court docket, USPTO Patent Trial and Appeal Board records, FDA listing history, and any settlement documents. The claim text itself does not establish whether US 10,857,159 has been litigated, challenged in an inter partes review, invalidated, disclaimed, or settled.

The principal legal vulnerabilities would likely include:

Written description support for the extremely low benzoic-acid range.
Enablement across the full concentration ranges.
Anticipation by earlier halobetasol foam or aerosol formulations.
Obviousness based on known ethanol, fatty alcohol, surfactant, propylene glycol, and hydrocarbon propellant systems.
Definiteness of "about," "storage stable," and the degradation-test requirement.
Proof that the accused product meets the 24-month degradation limitation.
Construction of "consisting of" in the presence of incidental ingredients or manufacturing residues.

The stability limitation may strengthen validity if the patent demonstrates an unexpected result. It may weaken enforcement if the required result cannot be established without lengthy real-time testing or if the claim does not specify a sufficiently reproducible analytical method.

How does this patent compare with broader halobetasol patent protection?

Protection type	Scope	Risk to generic entrant
Active-ingredient patent	Chemical compound or salt/ester	Usually broad, but potentially expired earlier
Formulation patent	Specific excipient and concentration system	High if the generic matches the formulation
Method-of-use patent	Treatment of a specified dermatologic condition	Depends on labeling and induced-infringement facts
Device or packaging patent	Canister, valve, actuator, or delivery system	Relevant to aerosol products
Manufacturing patent	Mixing, filling, or stabilization process	Relevant if the generic uses the claimed process
US 10,857,159	Stable halobetasol foam composition	Narrower than a genus formulation patent, but technically specific

A generic may avoid one formulation patent while remaining exposed to other listed or unlisted patents. Patent clearance must therefore be conducted across the full family and product-specific Orange Book record, not by reviewing US 10,857,159 in isolation.

What generic launch scenarios exist?

Early launch after a successful Paragraph IV challenge

This is the highest-value scenario for a generic applicant. It requires a favorable court decision, settlement permitting early entry, or a determination that the patent is not enforceable against the proposed product.

Launch with a non-infringing formulation

A generic could modify one or more excipients, the propellant, pH, or preservative system. This may lower patent risk but increase formulation-development and FDA-approval risk.

Launch after patent expiry

This avoids the central patent barrier but sacrifices early-entry economics. The commercial value depends on the reference product's sales, competing topical corticosteroids, authorized generic activity, and remaining market exclusivity.

At-risk launch

An applicant could launch before final resolution. That strategy exposes the company to injunction risk, damages, enhanced damages, and potential disruption of commercial supply.

What commercial exposure does the patent create?

The patent's commercial exposure is concentrated in products using the claimed foam architecture. It is less relevant to halobetasol lotions, creams, ointments, or non-aerosol products that do not reproduce the claimed system.

The highest-risk product profile is a halobetasol propionate foam with:

40% to 60% ethanol;
30% to 40% water;
emulsifying wax and cetostearyl alcohol;
polyoxyl 20 cetostearyl ether;
propylene glycol;
trace benzoic acid below 0.0005%;
hydrocarbon propellant at 3.5% to 4.0%;
pH near 5.0 to 5.5; and
documented degradation below 2% after 24 months.

A competing product outside several of these parameters may have lower patent exposure, but it may also require greater clinical, CMC, and regulatory differentiation.

Key Takeaways

US 10,857,159 is a narrow, formulation-specific patent for a storage-stable halobetasol foam.
Claim 1 requires every listed ingredient, the stated concentration ranges, a propellant, pH of 4.0 to 6.3, and less than 2% halobetasol degradation after 24 months at 25°C.
Claims 2 and 3 target a canister using propane, n-butane, isobutane, or combinations at 3.25% to 5.75%, with claim 3 narrowing the range to 3.5% to 4.0%.
Claim 4 narrows the pH to about 5.0 to 5.5.
The "consisting of" transition and the narrow benzoic-acid range create potential design-around opportunities.
The patent does not independently protect all halobetasol products, all topical foams, or all methods of treating dermatologic disease.
Paragraph IV exposure depends on whether the patent is listed against the relevant FDA-approved product.
A complete launch assessment must consider the entire patent family, Orange Book records, prosecution history, litigation docket, and any terminal disclaimer or patent-term adjustment.

FAQs About US Patent 10,857,159

Does US 10,857,159 cover halobetasol propionate cream?

No. The disclosed claims require a foamable composition with a propellant and a defined aerosol formulation. A conventional cream would not satisfy those limitations.

Can a competitor avoid the patent by removing benzoic acid?

Potentially. Claim 1 requires benzoic acid in an amount greater than 0% and less than 0.0005%. A formulation with no benzoic acid would not literally satisfy that limitation, although other patents and the doctrine of equivalents may remain relevant.

Does claim 3 cover a product with 4.1% propellant?

Not literally under the stated 3.5% to 4.0% range. The product could still fall within claim 2's broader 3.25% to 5.75% range if all inherited limitations are met.

Is a pH of 6.5 outside the patent?

Yes, it is outside the express 4.0 to 6.3 pH range in claim 1 and outside the narrower 5.0 to 5.5 range in claim 4.

Does the patent protect the use of halobetasol for psoriasis?

The supplied claims are composition claims, not independent method-of-treatment claims. They protect the defined foam formulation rather than the therapeutic indication in the abstract.

References

United States Patent and Trademark Office. (2020). US Patent No. 10,857,159, halobetasol foam composition claims.
United States Code. (2023). 35 U.S.C. §§ 154 and 156.
United States Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Code. (2023). 21 U.S.C. § 355(j), abbreviated new drug applications and patent certifications.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mayne Pharma	LEXETTE	halobetasol propionate	AEROSOL, FOAM;TOPICAL	210566-001	May 24, 2018		DISCN	Yes	No	10,857,159*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016372789	⤷ Start Trial
Brazil	112018012349	⤷ Start Trial
Canada	3008753	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,857,159

Which drugs does patent 10,857,159 protect, and when does it expire?

Summary for Patent: 10,857,159